Preclinical evidence for the therapeutic value of TBX5 normalization in arrhythmia control.

MLA

Rathjens, Franziska S., et al. “Preclinical Evidence for the Therapeutic Value of TBX5 Normalization in Arrhythmia Control.” Cardiovascular Research, vol. 117, no. 8, July 2021, pp. 1908–22. EBSCOhost, https://doi.org/10.1093/cvr/cvaa239.

APA

Rathjens, F. S., Blenkle, A., Iyer, L. M., Renger, A., Syeda, F., Noack, C., Jungmann, A., Dewenter, M., Toischer, K., El-Armouche, A., Müller, O. J., Fabritz, L., Zimmermann, W.-H., Zelarayan, L. C., & Zafeiriou, M.-P. (2021). Preclinical evidence for the therapeutic value of TBX5 normalization in arrhythmia control. Cardiovascular Research, 117(8), 1908–1922. https://doi.org/10.1093/cvr/cvaa239

Chicago

Rathjens, Franziska S, Alica Blenkle, Lavanya M Iyer, Anke Renger, Fahima Syeda, Claudia Noack, Andreas Jungmann, et al. 2021. “Preclinical Evidence for the Therapeutic Value of TBX5 Normalization in Arrhythmia Control.” Cardiovascular Research 117 (8): 1908–22. doi:10.1093/cvr/cvaa239.